Olema Oncology, Inc.
OLMA · XNASCIK 1750284fmd_0VQB6PD77MR82G6XZKYQAMFMABManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 4 | 14 | 51 | 82 | 86 | 125 | 158 |
| Total operating expenses | 4 | 22 | 71 | 107 | 105 | 142 | 179 |
| Operating income | (4) | (22) | (71) | (107) | (105) | (142) | (179) |
| Interest expense | – | 1 | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 2 | 8 | 13 | 16 |
| Other non-operating income (expense) | 0 | (1) | 0 | 2 | 8 | 13 | 16 |
| Income before taxes | – | – | – | – | – | (129) | (162) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (129) | (162) |
| Net income | (4) | (22) | (71) | (105) | (97) | (129) | (162) |
| Net income to common shareholders | (4) | (24) | (71) | – | – | – | – |